Bivariate analysis Multivariate analysis, n = 793
  Occurrence Cox   Fine-Gray   Cox Fine-Gray
Characteristics n = 1136 % HR$crude[80% CI] P SHRcrude[80% CI] P HRajusted[95% CI] P* SHRajusted[95% CI] P*

Year of first HAART

0.1448

0.0043

 

0.3461

0.0191

[2000–2001]

43

13.74

1(Reference)

1(Reference)

1(Reference)

1(Reference)

[2002–2003]

32

13.22

1.18 [0.87–1.59]

1.02 [0.76–1.38]

1.09 [0.59–1.98]

0.97 [0.55–1.73]

[2004– 2005]

16

  6.32

0.72 [0.49–1.06]

0.50 [0.34–0.73]

0.53 [0.23–1.21]

0.36 [0.16–0.78]

[2006– 2008]

10

  3.05

0.55 [0.34–0.87]

0.38 [0.24–0.59]

0.68 [0.27–1.72]

0.43 [0.17–1.06]

First HAART regimen

0.0001

0.0001

0.0060

0.0444

2NRTI + 1PI/1PIb

19

  4.68

1(Reference)

1(Reference)

1(Reference)

1(Reference)

2NRTI + 1NNRTI

28

  7.37

1.20 [0.82–1.77]

1.53 [1.04–2.24]

1.70 [0.79–3.67]

1.82 [0.84–3.94]

 Other regimens

54

15.43

2.66 [1.88–3.75]

2.86 [2.03–4.02]

2.94 [1.47–5.88]

2.38 [1.20–4.71]

HIV seropositivity duration (years)

0.0032

0.0011

0.0094

0.0039

<0.169

28

  9.89

1(Reference)

1(Reference)

1(Reference)

1(Reference)

[0.16– 1.83]

13

  4.56

0.45 [0.29–0.69]

0.49 [0.32–0.76]

0.64 [0.29–1.39]

0.68 [0.30–1.52]

[1.83– 8.27]

18

  6.34

0.56 [0.38–0.82]

0.65 [0.44–0.95]

0.80 [0.35–1.83]

0.68 [0.30–1.53]

[8.27– 24.02]

42

14.79

1.19 [0.87–1.63]

1.45 [1.06–1.99]

1.92 [1.04–3.54]

1.94 [1.05–3.58]

AIDS-defining illness

n=1092

100%

0.0059

0.1239

0.0311

0.1201

No

76

  8.08

1(Ref)

1(Ref)

1(Ref)

1(Ref)

Yes

18

11.92

2.06 [1.47–2.88]

1.50 [1.07–2.11]

2.05 [1.06–3.95]

1.74 [0.86–3.50]

* P-value obtained by backward stepwise regression
** Ti =Time of HAART initiation
PIb = boosted protease inhibitor
$ Hazard Ratio obtained by Cox model
Subdistribution Hazards Ratio obtained by Fine-Gray model
Table 3: Baseline risk factors of first line HAART discontinuation for treatment failure: Cox and Fine-Gray models.
Goto home»